NZ603345A - Stabilized ophthalmic galactomannan formulations - Google Patents

Stabilized ophthalmic galactomannan formulations

Info

Publication number
NZ603345A
NZ603345A NZ603345A NZ60334511A NZ603345A NZ 603345 A NZ603345 A NZ 603345A NZ 603345 A NZ603345 A NZ 603345A NZ 60334511 A NZ60334511 A NZ 60334511A NZ 603345 A NZ603345 A NZ 603345A
Authority
NZ
New Zealand
Prior art keywords
sorbitol
galactomannan
concentration
present
stabilized ophthalmic
Prior art date
Application number
NZ603345A
Other languages
English (en)
Inventor
David L Meadows
Howard Allen Ketelson
James W Davis
Original Assignee
Alcon Res Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Alcon Res Ltd filed Critical Alcon Res Ltd
Publication of NZ603345A publication Critical patent/NZ603345A/en

Links

Classifications

    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00Medicinal preparations characterised by special physical form
    • A61K9/0012Galenical forms characterised by the site of application
    • A61K9/0048Eye, e.g. artificial tears
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/70Carbohydrates; Sugars; Derivatives thereof
    • A61K31/715Polysaccharides, i.e. having more than five saccharide radicals attached to each other by glycosidic linkages; Derivatives thereof, e.g. ethers, esters
    • A61K31/736Glucomannans or galactomannans, e.g. locust bean gum, guar gum
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/08Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
    • A61K47/10Alcohols; Phenols; Salts thereof, e.g. glycerol; Polyethylene glycols [PEG]; Poloxamers; PEG/POE alkyl ethers
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/26Carbohydrates, e.g. sugar alcohols, amino sugars, nucleic acids, mono-, di- or oligo-saccharides; Derivatives thereof, e.g. polysorbates, sorbitan fatty acid esters or glycyrrhizin
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00Medicinal preparations characterised by special physical form
    • A61K9/08Solutions
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00Drugs for disorders of the senses
    • A61P27/02Ophthalmic agents
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00Drugs for disorders of the senses
    • A61P27/02Ophthalmic agents
    • A61P27/04Artificial tears; Irrigation solutions

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Epidemiology (AREA)
  • Ophthalmology & Optometry (AREA)
  • Molecular Biology (AREA)
  • Engineering & Computer Science (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Oil, Petroleum & Natural Gas (AREA)
  • Biochemistry (AREA)
  • Medicinal Preparation (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
NZ603345A 2010-05-05 2011-05-04 Stabilized ophthalmic galactomannan formulations NZ603345A (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US33151110P 2010-05-05 2010-05-05
PCT/US2011/035165 WO2011140203A2 (en) 2010-05-05 2011-05-04 Stabilized ophthalmic galactomannan formulations

Publications (1)

Publication Number Publication Date
NZ603345A true NZ603345A (en) 2014-12-24

Family

ID=44626461

Family Applications (1)

Application Number Title Priority Date Filing Date
NZ603345A NZ603345A (en) 2010-05-05 2011-05-04 Stabilized ophthalmic galactomannan formulations

Country Status (16)

Country Link
US (2) US20110275593A1 (enExample)
EP (1) EP2566447B1 (enExample)
JP (1) JP5794744B2 (enExample)
KR (2) KR20130060228A (enExample)
CN (2) CN102939074A (enExample)
AR (1) AR081015A1 (enExample)
AU (1) AU2011248129B2 (enExample)
BR (1) BR112012028308B1 (enExample)
CA (1) CA2798069C (enExample)
ES (1) ES2809304T3 (enExample)
MX (1) MX2012012826A (enExample)
NZ (1) NZ603345A (enExample)
SG (2) SG10201804305SA (enExample)
TW (1) TWI606841B (enExample)
WO (1) WO2011140203A2 (enExample)
ZA (1) ZA201208199B (enExample)

Families Citing this family (18)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CL2009000985A1 (es) * 2008-04-26 2010-01-15 Alcon Res Ltd Composicion oftalmica que comprende entre 0,16 y 0,19% p/v de un galactomanano, alrededor de 0,7% p/v de un borato, cis-diol y menos de 5 ppm de concentracion de cationes divalentes; y su uso para lubricar el ojo.
TWI492769B (zh) * 2009-09-23 2015-07-21 Alcon Res Ltd 可注射的水性眼用組成物及其使用之方法
TW201336527A (zh) * 2012-02-10 2013-09-16 Alcon Res Ltd 具增強的穩定性之水性藥學組成物
UA113434C2 (uk) * 2012-05-04 2017-01-25 Алкон Рісерч, Лтд. Офтальмологічна композиція з поліпшеним захистом від зневоднювання й утриманням
EP3340982B1 (en) 2015-08-26 2021-12-15 Achillion Pharmaceuticals, Inc. Compounds for treatment of immune and inflammatory disorders
AR106018A1 (es) 2015-08-26 2017-12-06 Achillion Pharmaceuticals Inc Compuestos de arilo, heteroarilo y heterocíclicos para el tratamiento de trastornos médicos
KR20190036520A (ko) 2016-06-27 2019-04-04 아칠리온 파르마세우티칼스 인코포레이티드 의학적 장애를 치료하기 위한 퀴나졸린 및 인돌 화합물
CN115089547A (zh) * 2016-10-12 2022-09-23 Ps治疗有限公司 人工泪液、隐形眼镜和药物载体组合物及其使用方法
US11583496B2 (en) 2016-10-12 2023-02-21 PS Therapy Inc. Drug vehicle compositions and methods of use thereof
US11260035B2 (en) 2016-10-12 2022-03-01 Ps Therapies Ltd Topical compositions and methods of use thereof
AU2018227849B2 (en) 2017-03-01 2022-04-28 Achillion Pharmaceuticals, Inc. Aryl, heteroaryl, and heterocyclic pharmaceutical compounds for treatment of medical disorders
EP3841086B1 (en) 2018-08-20 2025-04-23 Achillion Pharmaceuticals, Inc. Pharmaceutical compounds for the treatment of complement factor d medical disorders
JP7443375B2 (ja) 2018-09-06 2024-03-05 アキリオン ファーマシューティカルズ, インコーポレーテッド 医学的障害の治療のための大環状化合物
JP7504088B2 (ja) 2018-10-16 2024-06-21 ジョージア ステイト ユニバーシティー リサーチ ファウンデーション インコーポレイテッド 医学的障害の治療のための一酸化炭素プロドラッグ
TWI757773B (zh) 2019-06-28 2022-03-11 瑞士商愛爾康公司 眼用組成物
JP2023515073A (ja) 2020-02-20 2023-04-12 アキリオン ファーマシューティカルズ, インコーポレーテッド 補体因子d媒介障害の処置用のヘテロアリール化合物
US20250171423A1 (en) 2020-09-23 2025-05-29 Achillion Pharmaceuticals, Inc. Pharmaceutical compounds for the treatment of complement mediated disorders
WO2025186703A1 (en) 2024-03-04 2025-09-12 Alcon Inc. Carbamoylphenylboronic acid-containing acrylic monomers and uses thereof

Family Cites Families (13)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US8028A (en) * 1851-04-08 Hokse-poweb
US4136173A (en) * 1977-01-31 1979-01-23 American Home Products Corp. Mixed xanthan gum and locust beam gum therapeutic compositions
DE3827561C1 (enExample) * 1988-08-13 1989-12-28 Lts Lohmann Therapie-Systeme Gmbh & Co Kg, 5450 Neuwied, De
US5505953A (en) * 1992-05-06 1996-04-09 Alcon Laboratories, Inc. Use of borate-polyol complexes in ophthalmic compositions
DE69839355T2 (de) * 1997-07-29 2009-06-04 Alcon Laboratories, Inc., Fort Worth Ophthalmische Zusammensetzungen enthaltend Galaktomannanpolymere und Borat
GB9808461D0 (en) * 1998-04-22 1998-06-17 Innovative Tech Ltd Solid borate-diol interaction products
US7084130B2 (en) * 2001-12-11 2006-08-01 Alcon, Inc. Intraocular irrigating solution having improved flow characteristics
TWI336257B (en) * 2003-06-13 2011-01-21 Alcon Inc Ophthalmic compositions containing a synergistic combination of three polymers
WO2008036855A2 (en) * 2006-09-21 2008-03-27 Alcon Research, Ltd. Self-preserved aqueous pharmaceutical compositions
TWI434926B (zh) 2006-12-11 2014-04-21 Alcon Res Ltd 眼用組成物中聚氧化乙烯-聚氧化丁烯(peo-pbo)嵌段共聚物之使用
TW200904485A (en) * 2007-05-18 2009-02-01 Alcon Res Ltd Phospholipid compositions for contact lens care and preservation of pharmaceutical compositions
CL2009000985A1 (es) * 2008-04-26 2010-01-15 Alcon Res Ltd Composicion oftalmica que comprende entre 0,16 y 0,19% p/v de un galactomanano, alrededor de 0,7% p/v de un borato, cis-diol y menos de 5 ppm de concentracion de cationes divalentes; y su uso para lubricar el ojo.
WO2010091287A1 (en) 2009-02-05 2010-08-12 Alcon Research, Ltd. Process for purifying guar

Also Published As

Publication number Publication date
US20130244971A1 (en) 2013-09-19
SG10201804305SA (en) 2018-06-28
BR112012028308B1 (pt) 2021-09-28
BR112012028308A2 (pt) 2016-11-01
WO2011140203A2 (en) 2011-11-10
EP2566447B1 (en) 2020-07-15
MX2012012826A (es) 2013-01-28
CA2798069C (en) 2016-07-05
CN106389325A (zh) 2017-02-15
KR20130060228A (ko) 2013-06-07
AU2011248129B2 (en) 2014-10-09
US20110275593A1 (en) 2011-11-10
ES2809304T3 (es) 2021-03-03
JP2013525493A (ja) 2013-06-20
TWI606841B (zh) 2017-12-01
WO2011140203A3 (en) 2012-04-19
AU2011248129A1 (en) 2012-11-29
KR20180001587A (ko) 2018-01-04
CN102939074A (zh) 2013-02-20
EP2566447A2 (en) 2013-03-13
US8846641B2 (en) 2014-09-30
TW201141524A (en) 2011-12-01
SG185422A1 (en) 2012-12-28
JP5794744B2 (ja) 2015-10-14
ZA201208199B (en) 2014-01-29
AR081015A1 (es) 2012-05-30
CA2798069A1 (en) 2011-11-10

Similar Documents

Publication Publication Date Title
NZ603345A (en) Stabilized ophthalmic galactomannan formulations
MD20150050A2 (ro) Soluţii midriatice şi antiinflamatorii stabile fără conservanţi pentru injectare
MX2021007794A (es) Composiciones y metodos para aplicaciones oftalmicas y/u otras aplicaciones.
MX2020005217A (es) Composicion oftalmica y dispositivo de administracion de la misma.
MX2015002239A (es) Formulacion oftalmica de lipido polioxilo o de acido graso polioxilo y tratamiento de padecimientos oculares.
PH12015501421A1 (en) Long-acting formulations of insulin
MX2012006881A (es) Composiciones de povidona-yodo oftalmicas no irritantes.
PH12014502778B1 (en) Antibody formulation
AU2013334740A8 (en) Stable, low viscosity antibody formulation
AR084932A1 (es) Composicion oftalmica que comprende un androgeno y su uso para la fabricacion de un medicamento util para el tratamiento de una enfermedad ocular resultante de una deficiencia androgenica
BR112015000520A2 (pt) agente de espessamento estável com lipase
PE20160681A1 (es) Formulacion de premezcla de dexmedetomidina
CO7151500A2 (es) Preparación inyectable
MX389346B (es) Formulaciones de anticuerpos monoclonales de alta concentración.
IN2014MN01470A (enExample)
EA201492290A1 (ru) Составы и способы для вагинальной доставки антипрогестинов
MX345042B (es) Composiciones y métodos para tratamiento no quirúrgico de ptosis.
UA118576C2 (uk) Фармацевтична композиція, яка містить бринзоламід
UA113962C2 (xx) Фармацевтична композиція, яка містить апоморфін як активний інгредієнт
WO2014153009A3 (en) Thiosaccharide mucolytic agents
UA116886C2 (uk) Препаративна форма йодосульфурон-метилу натрієвої солі
PH12014502571B1 (en) Ophthalmic compositions with improved dessication protection and retention
MY175764A (en) Extended-release formulation for reducing the frequency of urination and method of use thereof
MX2016015211A (es) Formulaciones topicas y usos de las mismas.
IN2014MN00929A (enExample)

Legal Events

Date Code Title Description
PSEA Patent sealed
RENW Renewal (renewal fees accepted)

Free format text: PATENT RENEWED FOR 1 YEAR UNTIL 04 MAY 2016 BY FB RICE

Effective date: 20150325

RENW Renewal (renewal fees accepted)

Free format text: PATENT RENEWED FOR 1 YEAR UNTIL 04 MAY 2017 BY CPA GLOBAL

Effective date: 20160318

RENW Renewal (renewal fees accepted)

Free format text: PATENT RENEWED FOR 1 YEAR UNTIL 04 MAY 2018 BY CPA GLOBAL

Effective date: 20170418

RENW Renewal (renewal fees accepted)

Free format text: PATENT RENEWED FOR 1 YEAR UNTIL 04 MAY 2019 BY CPA GLOBAL

Effective date: 20180419

RENW Renewal (renewal fees accepted)

Free format text: PATENT RENEWED FOR 1 YEAR UNTIL 04 MAY 2020 BY CPA GLOBAL

Effective date: 20190418

ASS Change of ownership

Owner name: ALCON INC., CH

Effective date: 20191218

LAPS Patent lapsed